Global levels of histone modifications predict prostate cancer recurrence

Epigenetic alterations such as DNA methylation and histone modifications play important roles in carcinogenesis. It was reported that global histone modification patterns are predictors of cancer recurrence in various tumor entities. Our study was performed to evaluate histone lysine (HxKy) and histone acetyl (HxAc) modifications in prostate tissue.

[1]  S. Horvath,et al.  Global levels of histone modifications predict prognosis in different cancers. , 2009, The American journal of pathology.

[2]  Daniele Soria,et al.  Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. , 2009, Cancer research.

[3]  P. Maxwell,et al.  Changes in chromatin phenotype predict the response to hormonal deprivation therapy in patients with prostate cancer , 2009, BJU international.

[4]  R. Montironi,et al.  Immunohistochemical Evaluation of Global DNA Methylation and Histone Acetylation in Papillary Urothelial Neoplasm of Low Malignant Potential , 2008, International journal of immunopathology and pharmacology.

[5]  S. Jang,et al.  The Global Histone Modification Pattern Correlates with Cancer Recurrence and Overall Survival in Gastric Adenocarcinoma , 2008, Annals of Surgical Oncology.

[6]  K. Helin,et al.  Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. , 2008, Genes & development.

[7]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[8]  W. Weichert,et al.  Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy , 2008, British Journal of Cancer.

[9]  Yang Shi,et al.  Histone lysine demethylases: emerging roles in development, physiology and disease , 2007, Nature Reviews Genetics.

[10]  G. Giaccone,et al.  Global histone modifications predict prognosis of resected non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Dustin E. Schones,et al.  High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.

[12]  A. Partin,et al.  Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Osama Sharaf,et al.  Epigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma , 2007, BJU international.

[14]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[15]  J. Ellinger,et al.  Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. , 2007, European urology.

[16]  T. Kouzarides.  Chromatin Modifications and Their Function , 2007, Cell.

[17]  Peter W Hamilton,et al.  Histone acetylation and chromatin pattern in cancer. A review. , 2007, Analytical and quantitative cytology and histology.

[18]  N. Cho,et al.  Hypermethylation of CpG island loci and hypomethylation of LINE‐1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features , 2007, The Journal of pathology.

[19]  T. Barrette,et al.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. , 2007, Neoplasia.

[20]  R. Schüle,et al.  Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. , 2006, Cancer research.

[21]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[22]  S. Horvath,et al.  Global histone modification patterns predict risk of prostate cancer recurrence , 2005, Nature.

[23]  A. Wellmann,et al.  Diagnostic and Prognostic Information in Prostate Cancer with the Help of a Small Set of Hypermethylated Gene Loci , 2005, Clinical Cancer Research.

[24]  R Engers,et al.  Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation , 2004, British Journal of Cancer.

[25]  M. Becich,et al.  Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Jeanne Kowalski,et al.  Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer , 2004, Cancer Research.

[27]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[29]  W. Remmele,et al.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.